SCHEMBL13993667

SCHEMBL13993667

CN1CCN(CCS(=O)(=O)N2CCC(NC(=O)c3n[nH]cc3NC(=O)c3c(Cl)cccc3Cl)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK14 O94921 19/20 0.46
▸ CCNY Q8ND76 17/20 0.46
▸ CCNT1 O60563 2/20 0.42
▸ CDK9 P50750 2/20 0.42
▸ CDK5 Q00535 2/20 0.42
▸ CDK5R1 Q15078 2/20 0.42
▸ CASK O14936 1/20 0.41
▸ CDKL5 O76039 1/20 0.41
▸ CCNB2 O95067 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ MAK P20794 1/20 0.41
▸ CDK11B P21127 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ CCNE1 P24864 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ CCND3 P30281 1/20 0.41
▸ CLK1 P49759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263071 0.94 CDK14 (0.44) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL13993666 0.91 CDK14 (0.42) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL2030754 0.89 CDK14 (0.49) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL2031219 0.89 CDK14 (0.51) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL13993670 0.89 CDK14 (0.42) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL8262598 0.88 CDK14 (0.46) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL8261496 0.88 CDK14 (0.46) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL13993668 0.88 CDK14 (0.46) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL5007794 0.87 CDK14 (0.47) CDK14CCNY
SCHEMBL8262073 0.86 CDK14 (0.47) CDK14CCNYCCNT1CDK9CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 — — US disclosed
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S GSK3A, CDK11A, CDK1 CDK14 8/4885CCNY 51/4885CCNT1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback